Progression-free survival of 1059 early PET-negative patients who were treated according to the initial protocol. Shown are the rates of progression-free survival of the (a) favorable (F) groups of patients randomly assigned to doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) plus involved-node radiotherapy (INRT; n  =  227) or ABVD only (n  =  238) and of the (b) unfavorable (U) groups randomly assigned to ABVD plus INRT (n   =   292) or ABVD only (n  =  302). HR  =  hazard ratio; O  =  observed; n  =  number of patients. Previously published in: André MPE, Girinsky T, Federico M, et al. Early positron emission tomography response-adapted treatment in stage I and II Hodgkin lymphoma: final results of the randomized EORTC/LYSA/FIL H10 trial. J Clin Oncol. 2017;35(16):1786-1794.¹⁹  doi: 10.1200/JCO.2016.68.6394. Reproduced with permission from the American Society of Clinical Oncology.